Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment

This study has been completed.
Sponsor:
Information provided by:
University of Athens
ClinicalTrials.gov Identifier:
NCT00534443
First received: September 21, 2007
Last updated: August 8, 2011
Last verified: June 2008

September 21, 2007
August 8, 2011
February 2007
September 2009   (final data collection date for primary outcome measure)
Effect of treatment on changes of cytokines levels in serum of patients [ Time Frame: Baseline and 8 weeks ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00534443 on ClinicalTrials.gov Archive Site
Effect of treatment on changes of cytokines levels in supernatants of cultures of gastric mucosa [ Time Frame: Baseline and 8 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment
A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease

Although all PPIs are effective, there are some differences in their clinical performance, particularly in terms of the degree and speed of gastric acid suppression. Few data are also available about their effect of the pathophysiological mechanisms of gastritis and peptic ulcer disease. Aim of the present study is to investigate the effect of therapy with esomeprazole or rabeprazole on the mechanism of pathogenesis of gastritis and particularly on the pattern of release of pro- and anti- inflammatory cytokines associated to peptic ulcerative process by the gastric mucosa.

Although all PPIs are effective, there are some differences in their clinical performance, particularly in terms of the degree and speed of gastric acid suppression. Few data are also available about their effect of the pathophysiological mechanisms of gastritis and peptic ulcer disease.

Triggering receptor expressed on myeloid cells (TREM)-1 is a recently discovered receptor expressed on the surface of neutrophils and monocytes. Engagement of TREM-1 has been reported to trigger the synthesis of proinflammatory cytokines. A soluble form of TREM-1, named sTREM-1, was observed and identified at significant levels in serum samples from patients with disease of the gastrointestinal tract inflammatory bowel disease. rendering interest about the implication of sTREM-1 in their pathogenesis.

sTREM-1 was also found elevated in the gastric juice of patients with peptic ulcer disease being correlated to the degree of the infiltration of the gastric mucosa by neutrophils.

Published data of our group elicit that sTREM-1 secretion is a crucial parameter for evolution from chronic gastritis to peptic ulcer disease. Samples of biopsies of gastric mucosa were cultured in the absence/presence of endotoxins showing that the inflamed mucosa was a potent secretor of sTREM-1 whatever ceased to exist post-antisecretory treatment.

Aim of the present study is to investigate the effect of therapy with esomeprazole or rabeprazole on the mechanism of pathogenesis of gastritis and particularly on the pattern of release of pro- and anti- inflammatory cytokines associated to peptic ulcerative process by the gastric mucosa.

Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Peptic Ulcer
Procedure: Endoscopy of upper GI tract

Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.

Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines.

Other Name: Gastroscopy
Experimental: 1
A total of 130 patients with peptic ulcer disease and /or chronic gastritis will be enrolled in the study after written informed consent. Patients will be prescribed oral treatment with rabeprazole or esomeprazole according to standard guidelines. Rabeprazole is administered 20mg twice daily and esomeprazole 10 mg once daily. Selection of rabeprazole or esomeprazole is at the discretion of the attending physicians. The drug is administered for four weeks in patients with duodenal ulcers, for eight weeks in patients with gastric ulcers and for four weeks in patients with chronic gastritis.
Intervention: Procedure: Endoscopy of upper GI tract

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
September 2009
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent.
  • Abdominal pain or discomfort and/or
  • Epigastric pain with nausea and vomiting and/or
  • Dyspepsia.

Exclusion Criteria:

  • Recent upper GI bleeding
  • Gastric carcinoma
  • Diabetes mellitus
  • Liver cirrhosis
  • Acute or chronic renal failure
  • The ingestion of any antimicrobial or antisecretory medication for at least 15 days prior to endoscopy.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Greece
 
NCT00534443
3530
Yes
Evangelos Giamarellos-Bourboulis, University of Athens, Medical School, Greece
University of Athens
Not Provided
Study Chair: Evangelos J. Giamarellos-Bourboulis, MD, PhD 4th Department of Internal Medicine, ATTIKON University Hospital, 124 62 Athens, Greece
Principal Investigator: Vassileios Koussoulas, MD, PhD Department of Endoscopy, Sismanoglion General Hospital, 151 26 Athens, Greece
University of Athens
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP